Advisory Research Inc Avadel Pharmaceuticals PLC Transaction History

Advisory Research Inc

  • $512 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
SELL
$9.64 - $14.59 $929,826 - $1.41 Million
-96,455 Reduced 47.96%
104,654 $1.48 Million
Q3 2023

Nov 13, 2023
SELL
$10.3 - $15.99 $710,370 - $1.1 Million
-68,968 Reduced 25.54%
201,109 $2.07 Million
Q2 2023

Aug 14, 2023
BUY
$8.48 - $16.48 $2.29 Million - $4.45 Million
270,077 New
270,077 $4.45 Million

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Advisory Research Inc Portfolio

Follow Advisory Research Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Research Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email